ClinicalTrials.gg
RecruitingNCT04460352NEEDSUpdated Mar 6, 2025

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

A Phase 3 interventional study of Neoadjuvant radiotherapy (arm A) and Carboplatin, paclitaxel in Esophageal Squamous Cell Carcinoma, sponsored by Karolinska University Hospital. Recruiting at 12 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Karolinska University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,020
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies testing cisplatin in Esophageal Squamous Cell Carcinoma — 6 open to participants now, 7 under way, 2 of them phase 3. Cisplatin · Esophageal Squamous Cell Carcinoma.

Planned enrollment
Largest of 41
1,020 · median 48
Started
2020
with 1 other
Phase 3
6 of 44
2 open now
Registered
38th of 44
by date

Among the 44 studies testing cisplatin in Esophageal Squamous Cell Carcinoma, this one has the largest planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 3, and was the 38th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

6 of the 44 studies testing cisplatin in Esophageal Squamous Cell Carcinoma are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing cisplatin in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention definitive chemoradiotherapy. A second co-primary endpoint is global health related quality of life (HRQOL) one year after randomisation. A third co-primary endpoint is eating restictions one year after randomisation.

The aim is to compare outcomes after neoadjuvant chemoradiotherapy with subsequent esophagectomy to definitive chemoradiotherapy with surveillance and salvage esophagectomy as needed in patients with resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, with the aim to provide generalisable guidance for future clinical practice.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • Neoadjuvant chemoradiotherapy
  • Definitive chemoradiotherapy with salvage surgery as needed
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically confirmed SCC of the esophagus in locally advanced stages cT1 N+ or cT2-4a any N, M0, according to current (8th) version of of the AJCC TNM classification.
  • Technically resectable disease according to the local multidisciplinary team conference (MDT)/tumor board.
  • Performance status 0-1.
  • Adequate organ function.
  • Women of (WOCBP*) must have a negative serum or urine pregnancy test.
  • Patients of childbearing/ should use highly effective method of measures during the study treatment period and for at least five months after the last study treatment.
  • Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
  • Before patient registration/randomization, written must be given according to ICH/GCP/GDPR and national/local regulations.

Exclusion criteria

Exclusion Criteria:

  • M1 according to current (8th) version of of the AJCC TNM classification.
  • cT4b according to current (8th) version of of the AJCC TNM classification.
  • Primary tumor not resectable without laryngectomy.
  • Impaired renal, hepatic, cardiac, pulmonary or endocrine status that compromises the eligibility of the patient for multimodality treatment with chemoradiotherapy followed by esophagectomy.
  • Subjects not considered likely to tolerate multimodality treatment with chemoradiotherapy followed by esophagectomy.
  • Subjects with previous are excluded unless a complete remission or complete resection was achieved at least 5 years prior to study entry.
  • Prior or concomitant treatment with radiotherapy or chemoradiotherapy with potential overlap of radiotherapy fields.
  • Known uncontrollable to the components of the chemotherapeutic agents used in the trial regimens.
  • Inability to fully understand and digest study patient information or to comply with study instructions due to language difficulty or cognitive failure such as dementia or severe psychiatric disorder.

(Criteria slightly shortened)

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,020 participants (estimated)

Study arms

  • Active comparator
    Control arm (A)

    Neoadjuvant chemoradiotherapy followed by esophagectomy. Radiotherapy: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy. Chemotherapy: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting on the first day of radiotherapy. Esophagectomy: Within 8 weeks of termination of chemoradiotherapy,

    Radiation: Neoadjuvant radiotherapy (arm A) · Drug: Carboplatin, paclitaxel · Procedure: Esophagectomy

  • Experimental
    Experimental arm (B)

    Definitive chemoradiotherapy followed by surveillance, and esophagectomy only in case of residual or recurrent locoregional cancer. Radiotherapy: Two alternative schemes: 1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy. 2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy. Chemotherapy: Three alternative regimens: 1. Platin-Taxane Regimen: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy. 2a. Platinum-Fluoropyrimidine Regimen: Cisplatin 75mg/m2 weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion weeks 1 and 5. 2b. FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion weeks 1, 3 and 5.

    Radiation: Neoadjuvant radiotherapy (arm B) · Drug: Carboplatin, paclitaxel · Drug: Cisplatin, paclitaxel · Drug: Oxaliplatin, calcium folinate, 5-fluorouracil · Procedure: Esophagectomy

Interventions

  • RadiationNeoadjuvant radiotherapy (arm A)

    1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.

  • DrugCarboplatin, paclitaxel

    Drug pages: CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy

    Also known as: Neoadjuvant chemotherapy

  • ProcedureEsophagectomy

    Esophagectomy performed within 8 weeks after termination of chemoradiotherapy

  • RadiationNeoadjuvant radiotherapy (arm B)

    Two alternative schemes: 1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy. 2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.

  • DrugCarboplatin, paclitaxel

    Drug pages: CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).

    Also known as: Neoadjuvant Platin-Taxane Regimen (alternative 1)

  • DrugCisplatin, paclitaxel

    Drug pages: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.

    Also known as: Platinum-Fluoropyrimidine Regimens (alternative 2a)

  • DrugOxaliplatin, calcium folinate, 5-fluorouracil

    Drug pages: OxaliplatinStudies of OxaliplatinOxaliplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LeucovorinStudies of LeucovorinLeucovorin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.

    Also known as: Platinum-Fluoropyrimidine Regimens (alternative 2b)

  • ProcedureEsophagectomy

    Esophagectomy only in case of residual or recurrent locoregional cancer.

06

What researchers measure

Primary outcomes

  1. Overall survival

    When 398 events have occurred

    Time frame: 3 years after randomisation

  2. Global Health-related quality of life (HRQOL)

    European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30, version 3.0 (EORTC QLQ-C30). The two items assessing global health and overall quality of life are responded to in seven categories ranging from 1 (very poor) to 7 (excellent).

    Time frame: 1 year after randomisation

  3. Eating restrictions

    EORTC QLQ-OG25 instrument. This instrument consists of 25 items covering upper gastric symptoms or problems in four categories ranging from 1 (Not at all) to 4 (Very much).

    Time frame: 1 year after randomisation

Secondary outcomes

  1. Health related quality of life of Cancer patients

    EORTC HRQOL Questionnaire QLQ-C30 version 3.0, 28 items ranging from 1 (no problems at all) to 4 (very much) and two items assessing global health and overall quality of life are responded to in seven categories ranging from 1 (very poor) to 7 (excellent).

    Time frame: At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation

  2. Health related quality of life, oesophageal specific.

    EORTC HRQOL gastresophageal-specific questionnaire EORTC QLQ-OG25. 25 items assessing symptoms or problems are responded to in four categories ranging from 1 (no problems) to 4 (very much).

    Time frame: At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation

  3. Health related quality of life, general health

    The EuroQoL Group's EQ-5D-5L questionnaire consisting of five dimensions ranging from No problems to Extreme problems or Unable to care.

    Time frame: At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation

  4. Event-free survival

    Time to relapse, initiation of any anti-tumor therapy beyond the study treatments (salvage surgery is considered a study treatment in the dCRT arm), or death, whichever comes first.

    Time frame: 5 years after randomisation

  5. Loco-regional and distant relapse rates

    Including the relation of relapse location to the radiation field

    Time frame: 5 years after randomisation

  6. Histopathological response according to Mandard in operated patients

    ypTNM including total and metastatic lymph node count, tumor free resection margins, R0

    Time frame: 5 years after randomisation

  7. Health economy

    Assessed including patient-level medical resource use and societal costs due to sick-leave and other non-medical costs. Quality-adjusted life years (QALYs) will be calculated using EQ-5D

    Time frame: At baseline and 6, 12, 24, 36 and 60 months after randomisation

  8. Surgical complications

    According to the Esophagectomy Complications Consensus Group (ECCG) and classified according to Clavien-Dindo

    Time frame: After surgery in operated patients, up to 5 years after randomisation

  9. Treatment-related adverse events and toxicity

    NCI-CTCAE Criteria version 5.0

    Time frame: Up to 5 years after randomisation

  10. Nutritional outcomes - weight

    Weight development. Weight (in kg) will be measured at all visits.

    Time frame: Up to 5 years after randomisation

  11. Nutritional outcomes - dysphagia

    Dysphagia will be evaluated at all visits according to the CTC adverse event scale, grading from 0 (no problems) to 4 (worst problems).

    Time frame: Up to 5 years after randomisation

  12. Gender stratified analyses of all endpoints

    Time frame: Up to 5 years after randomisation

07

Study locations

12 of 12 sites recruiting
08

References and documents

Publications

  • Nilsson M, Olafsdottir H, Alexandersson von Dobeln G, Villegas F, Gagliardi G, Hellstrom M, Wang QL, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-Haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh CS, Mummudi N, Joshi A, Ferri L, Wong RK, O'Callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong FM, Chao YK, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R, Rosati R, Piessen G, de Manzoni G, Lordick F. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Front Oncol. 2022 Jul 13;12:917961. doi: 10.3389/fonc.2022.917961. eCollection 2022. PubMed 35912196 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2026, 73 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 73 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2020
First posted
Jul 7, 2020
StartActual
Nov 27, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2031
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04460352
Collaborators
University of Leipzig, The Swedish Research Council
Responsible party
Magnus Nilsson (Professor, Karolinska University Hospital) — Principal investigator
First posted
Jul 7, 2020
Start date
Nov 27, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Mar 6, 2025

Study contacts

Magnus Nilsson, MD, PhD
Contact
magnus.nilsson@ki.se
+46-707-375186
Mats Hellström
Contact
mats.hellstrom@regionstockholm.se
Magnus Nilsson, MD, PhD
study chair · Karolinska University Hospital
Florian Lordick, MD, PhD
study chair · Leipzig University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Paclitaxel · Oxaliplatin · Leucovorin · Fluorouracil

Start the discussion